These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 24266856)

  • 1. Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small-cell lung cancer.
    Jakobsen JN; Santoni-Rugiu E; Sørensen JB
    Histopathology; 2014 Feb; 64(3):412-20. PubMed ID: 24266856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer.
    Jakobsen JN; Santoni-Rugiu E; Sørensen JB
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):645-52. PubMed ID: 24562672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients.
    Jakobsen JN; Santoni-Rugiu E; Sørensen JB
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):43-51. PubMed ID: 24220933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer.
    Jakobsen JN; Santoni-Rugiu E; Sørensen JB
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):131-7. PubMed ID: 24326616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
    Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
    Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
    Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer.
    Ou W; Sun HB; Ye X; Zhang BB; Yang H; Fang Q; Li P; Wang SY
    J Thorac Oncol; 2010 Jul; 5(7):1033-41. PubMed ID: 20502361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.
    Jakobsen JN; Santoni-Rugiu E; Ravn J; Sørensen JB
    Eur J Cancer; 2013 Jul; 49(11):2494-503. PubMed ID: 23639410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test.
    Kolek V; Grygarkova I; Hajduch M; Klein J; Cwiertka K; Neoral C; Langova K; Mihal V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Dec; 152(2):259-66. PubMed ID: 19219217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study.
    Ahmed S; Birnbaum AE; Safran HP; Dipetrillo TA; Aswad BI; Ready NE; Ng T
    J Thorac Oncol; 2011 Aug; 6(8):1432-4. PubMed ID: 21847062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
    J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected Stage III non-small-cell lung cancer: long-term results of a trimodality Phase II protocol.
    Hehr T; Friedel G; Steger V; Spengler W; Eschmann SM; Bamberg M; Budach W
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1376-81. PubMed ID: 19864078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.
    Xu XL; Zhang YP; Fang Y; Su D; Chen W; Feng JG; Li ZP; Mao WM
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C49-55. PubMed ID: 26323924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
    Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
    J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
    Thienelt CD; Bunn PA; Hanna N; Rosenberg A; Needle MN; Long ME; Gustafson DL; Kelly K
    J Clin Oncol; 2005 Dec; 23(34):8786-93. PubMed ID: 16246975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive and Prognostic Value of TUBB3, RRM1, APE1, and Survivin Expression in Chemotherapy-Receiving Patients with Advanced Non‑Small Cell Lung Cancer.
    Raungrut P; Tanyapattrapong S; Jirapongsak J; Geater SL; Thongsuksai P
    Asian Pac J Cancer Prev; 2023 Sep; 24(9):3003-3013. PubMed ID: 37774051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer.
    Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Tada H; Kajiwara S; Watanabe N; Okada M; Sakamoto J; Aoe M; Soh J; Miyoshi S; Hotta K; Matsuo K; Date H
    J Thorac Oncol; 2018 May; 13(5):699-706. PubMed ID: 29505900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.